Capravirine
Names
Preferred IUPAC name
{5-[(3,5-Dichlorophenyl)sulfanyl]-4-(propan-2-yl)-1-[(pyridin-4-yl)methyl]-1H-imidazol-2-yl}methyl carbamate
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27) ☒N
    Key: YQXCVAGCMNFUMQ-UHFFFAOYSA-N ☒N
  • InChI=1/C20H20Cl2N4O2S/c1-12(2)18-19(29-16-8-14(21)7-15(22)9-16)26(10-13-3-5-24-6-4-13)17(25-18)11-28-20(23)27/h3-9,12H,10-11H2,1-2H3,(H2,23,27)
    Key: YQXCVAGCMNFUMQ-UHFFFAOYAP
  • O=C(OCc2nc(c(Sc1cc(Cl)cc(Cl)c1)n2Cc3ccncc3)C(C)C)N
Properties
C20H20Cl2N4O2S
Molar mass 451.37 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer.[1][2] Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs.[3][4]

References

  1. ↑ PubChem. "Capravirine". pubchem.ncbi.nlm.nih.gov. Retrieved 2019-06-02.
  2. ↑ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
  3. ↑ "Capravirine - Anti-Retroviral Drug". Drug Development Technology. Retrieved 2019-06-02.
  4. ↑ "A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 23 June 2005. Retrieved 2019-06-02.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.